Intuitive Surgical Is Down 41%. J&J's Robot Makes the Case Ottava is real, but
ISRG's selloff looks ahead of the data͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌
͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌ ͏‌

Unsubscribe
<[link removed]>

September 13, 2026
View online ↗
<[link removed]>
Intuitive Surgical Is Down 41%. J&J's Robot Makes the Case
Ottava is real, but ISRG's selloff looks ahead of the data




J&J management steps into the Morgan Stanley Global Healthcare Conference on
Monday at 11:30 a.m. Eastern with a story the market has been pricing anxiously
for months. Johnson & Johnson will present at the Morgan Stanley 24th Annual
Global Healthcare Conference on September 14, 2026, with management
participating in a Fireside Chat at 11:30 a.m. Eastern Time. The subject
everyone expects them to address: what a controlled commercial rollout of
Ottava actually looks like, and how fast a genuinely novel robot can take share
from the most entrenched franchise in surgery.

America's Energy Armageddon

The expert Barron's describes as visionary premieres a global "shockumentary"

Discover how woke progressives played politics with the energy grid as part of
a potential plot to "blackout" the U.S. economy in 2026...

See firsthand who's being set up to prosper and who could be wiped out (FREE
to stream!)
<[link removed]>

Why This Stock Now

The trade here is not obvious, and that is exactly the point. J&J has a robot
with U.S. market authorization. Intuitive Surgical has lost roughly 41% from
its January 2025 peak. Which stock deserves attention right now? The answer is
ISRG, and the Ottava launch is the reason why.

The Business

J&J's OTTAVA is the world's first table-integrated soft tissue robotic system,
receiving FDA De Novo authorization on July 22, 2026, cleared for multiple
procedures in general surgery. OTTAVA integrates its four robotic arms directly
into the operating table instead of mounting them on carts or booms, and J&J
says this cuts the OR footprint by 30 to 50 percent versus traditional systems.
That is a real engineering difference. It is also, for now, the entire case.

Intuitive's position is something else entirely. The company grew its da Vinci
surgical system installed base to 11,710 systems as of June 30, 2026, an
increase of 12% compared with 10,488 as of June 30, 2025. Second quarter 2026
revenue came in at $2.89 billion, up 19% year over year. U.S. da Vinci
procedure growth in Q2 was approximately 12%, driven primarily by strong growth
in general surgery, most notably cholecystectomy, hernia repair, and
appendectomy. Those are procedures Ottava is authorized to perform.
Wall Street: "Let Me Buy Your Algorithm"

This 20-year trading veteran once created a stock algorithm so powerful, Wall
Street tried to buy it from him. Now, he's built a BRAND-NEW market-crushing
algo... and it's flashing a HUGE opportunity that's set to move THIS MONDAY.

Get the full details here while there's still time
<[link removed]>


Why Wall Street Is Paying Attention

Intuitive posted a clean Q2 beat on July 16 and fell about 14% the next
session after holding its full-year outlook steady rather than raising it. Six
days later, the FDA granted De Novo authorization to J&J's Ottava for multiple
general-surgery procedures, the first credible challenger in soft-tissue
surgery in two decades. Those two events in eight days handed the bears the
momentum.

The selloff has been severe enough that valuation is now doing real work.
Intuitive's forward GAAP price-to-earnings ratio of 38.63x sits 44% below its
five-year average of 69.35x, and the forward price-to-sales ratio of 10.53x is
38% below its five-year average of 17.02x. Both point to a stock trading at a
considerable discount to historical norms. The business has not changed. The
multiple has collapsed.

What's Driving the Opportunity

J&J's commercial launch is controlled and deliberate. Johnson & Johnson plans
to roll out OTTAVA through a controlled commercial launch with select U.S.
customers, prioritizing early adoption success while simultaneously pursuing
expanded indications and international regulatory approvals. That is not a
blitz. It is a measured entry into a market where Intuitive has 25 years of
surgeon relationships and clinical evidence.

As for J&J itself, Ottava is unlikely to move the financial needle soon. The
MedTech segment generated $8.9 billion in Q2 2026 sales, up 4.5% on a reported
basis, and while OTTAVA is unlikely to materially affect J&J's near-term
financial results during a limited rollout, successful adoption could
eventually strengthen its position in higher-growth surgical technology. Buying
JNJ for Ottava upside means waiting years for a business that accounts for a
fraction of a $200 billion company. The math is better on the other side.

Sub–$1 Copper-Gold Explorer Has Major-Company-Funded Drilling

Copper is at record highs. Gold just blasted to $5K. Yet one little-known
Australia-focused copper-gold explorer still trades below $1 as it advances
multiple projects across two premier mineral belts. Most importantly, drills
are turning – with one of the world's largest gold producers funding the work.
Add a deep treasury, tight share structure, pending drill results, and
potential new deals, and this under-the-radar small-cap has all the right
ingredients for a major breakout.

More Details Here...
<[link removed]>

What Could Go Wrong

The bear case on ISRG is straightforward: hospitals could use J&J's broader
surgical portfolio as leverage in contract negotiations, pressuring Intuitive
on instrument pricing. Ottava raises the risk that increased competition and
remanufactured or extended use instruments could pressure Intuitive Surgical's
recurring revenue, especially if hospitals use J&J's broader surgical portfolio
to negotiate pricing or shift volumes. Recurring instrument revenue is the
engine of Intuitive's economics. Any erosion there matters more than system
placements.

There is also the Monday conference itself. J&J management framing an
aggressive commercial cadence, specific placement targets, or early hospital
adoption data could rattle ISRG again before the underlying thesis has time to
work.

The Bottom Line

The stock the market is punishing is Intuitive Surgical, and the punishment
has been disproportionate. Morningstar analyst Alex Morozov wrote on September
7, 2026 that Intuitive continues to benefit from global adoption of robotic
surgery, and that his long-term positive view on the company's competitive
position is unchanged even as Medtronic and Johnson & Johnson have finally
arrived. A company growing revenue 19% with 11,710 installed systems and no
long-term debt is not a company in crisis. It is a company on sale because a
competitor finally showed up. Monday's conference is a catalyst for both
stocks. For ISRG, the selloff has already done most of the damage. The better
trade is owning the dominant franchise at a roughly 41% discount to where it
traded at its January 2025 peak, not the challenger that is still counting its
first placements.


DISCLAIMER
This is a paid advertisement for informational and educational purposes only
and does not constitute financial advice. Investing involves risk and may not
be suitable for all individuals. Past performance does not guarantee future
results.
Trading Stocks Now is operated by Investing Media Solutions, LLC. We are not
licensed financial advisors. Always consult with a certified financial
professional before making investment decisions.

IMPORTANT NOTICE AND DISCLAIMER
Investing Media Solutions, LLC ("IMS"), the owner of this website (the
"Website"), cannot guarantee the accuracy or completeness of the information
contained in any article, email, newsletter, or other publication posted on or
viewed in connection with this website (the "Publications"). The author or
authors of those Publications are solely responsible for their contents. IMS
has not done any research or due diligence into the markets, industries, or
companies which may appear or be mentioned in the Publications.IMS will NOT be
liable for any loss or damage caused by a reader's reliance on information
posted on the Website or contained in the Publications.

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational
purposes only. This Website and the Publications do not purport to be a
complete analysis of any company's financial position. This Website, the
Publications or any statements made in the Publications are not, and should not
be construed to be, personalized investment advice directed to or appropriate
for any particular individual.This Website or the statements made in the
Publications should NOT be relied upon for purposes of transacting in any
securities posted on the Website or mentioned in the Publications, nor should
they be construed as a personalized recommendation to you to buy, sell, or hold
any position in any security posted on this Website or mentioned in any
Publications.b>

SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those
mentioned in the Publications should do so with caution.Investing or
transacting in securities involves substantial risk; you may lose some, all, or
possibly more than your original investment.Readers bear responsibility for
their own investment research and decisions and should review all investment
decisions with a licensed or registered investment professional.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither IMS nor any of its respective owners or employees are registered or
licensed as a securities broker-dealer, broker, an investment advisor, or an
investment advisor representative with the U.S. Securities and Exchange
Commission (SEC), any state securities regulatory authority, or any
self-regulatory organization.


For full policies, see our: Disclaimer
<[link removed]> | Privacy
<[link removed]> | Terms
<[link removed]>

Trading Stocks Now
203 N La Salle Street, Suite 2100 | Chicago, IL 60601

unsubscribe
<[link removed]>